E92DD0CC-DD0F-469D-8357-228A4A67DBD6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.71747700394218
- age_years
- 36
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.650
- E2F_TARGETS+0.642
- DNA_REPAIR+0.548
- G2M_CHECKPOINT+0.548
- OXIDATIVE_PHOSPHORYLATION+0.543
- INTERFERON_ALPHA_RESPONSE+0.525
- MYC_TARGETS_V2+0.513
- INTERFERON_GAMMA_RESPONSE+0.492
- ALLOGRAFT_REJECTION+0.473
- MTORC1_SIGNALING+0.416
Top 10 suppressed
- KRAS_SIGNALING_DN-0.364
- HEDGEHOG_SIGNALING-0.302
- MYOGENESIS-0.282
- BILE_ACID_METABOLISM-0.266
- ESTROGEN_RESPONSE_EARLY-0.259
- HEME_METABOLISM-0.228
- UV_RESPONSE_DN-0.209
- APICAL_SURFACE-0.163
- APICAL_JUNCTION-0.104
- MITOTIC_SPINDLE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9 | — | — | 0.965 |
| 2 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.964 |
| 3 | E7BE221B-273D-4C04-BE79-366E6455EFBC | — | — | 0.959 |
| 4 | FCD3124F-0F41-448E-B2B9-D9934D4EC1A7 | — | — | 0.958 |
| 5 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.955 |
| 6 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.954 |
| 7 | AF548E30-7121-4F9F-A2CD-F1A540E9C4EE | — | — | 0.950 |
| 8 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.949 |
| 9 | B99430AD-6309-4B90-A0AA-A5B2FA746246 | — | — | 0.944 |
| 10 | 6410821A-1C6A-4F64-939F-196313B8F1E5 | — | — | 0.942 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.642 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.548 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.548 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.543 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.525 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.513 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.492 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.473 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.416 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.403 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.371 | Inavolisib | — uncovered |
| APOPTOSIS | 0.362 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.349 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.347 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.332 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.325 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.308 | Idelalisib | — uncovered |
| COAGULATION | 0.299 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.297 | Inavolisib | — uncovered |